您当前的位置:
Ketorolac tromethamine salt (Synonyms: 酮咯酸氨丁三醇; Ketorolac Tromethamine; Ketorolac tris salt; RS37619 tromethamine salt)
目录号: PC14168 纯度: ≥98%
CAS No. :74103-07-4
商品编号 规格 价格 会员价 是否有货 数量
PC14168-1g 1g ¥490.00 请登录
PC14168-5g 5g ¥2254.00 请登录
PC14168-10mM (in 1mL DMSO) 10mM (in 1mL DMSO) ¥539.00 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
Ketorolac tromethamine salt
中文别名
酮咯酸氨丁三醇;(+/-)-5-苯甲酰基-2,3-二氢-1H-吡咯里嗪-1-甲酸氨丁三醇盐;酮洛酸氨丁三醇;Ketorolac Tromethamine 酮咯酸氨丁三醇;酮铬酸胺三丁醇,酮铬酸胺三丁醇,;酮咯酸;酮咯酸氨丁三醇 USP标准品;酮咯酸氨丁三醇 标准品;酮咯酸氨丁三醇(尼松);酮咯酸氨三丁醇;辛太克斯(浮选剂);(±)-5-苯甲酰基-2,3-二氢-1H-吡咯里嗪-1-羧酸丁三醇氨盐;酮咯酸丁三醇铵盐
英文名称
Ketorolac tromethamine salt
英文别名
Ketorolac Tromethamine;(+/-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid tris(hydroxymethyl)methylamine salt;Toradol;Ketorolac tris salt;2-amino-2-(hydroxymethyl)propane-1,3-diol,5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid;Ketorolac (tromethamine salt);KETROLAC TROMETHAMINE;rac Ketorolac Tromethamine Salt;Ketorolac;Ketrolac.Tromethamine Salt;(±)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid tris salt;Acular;Acular LS;Acular PF;Ketorolac tromethamine salt;Acuvail;Syntex;Ketorolac trometamol;SPRIX;Acular Preservative Free;Ketorolac (Toradol);Lixidol;Dolac;2-amino-2-(hydroxymethyl)propane-1,3-diol 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylate;CPD000058461;Toradol (TN);(+/-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid tris salt;(+-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carbo
Cas No.
74103-07-4
分子式
C19H24N2O6
分子量
376.40
包装储存

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

生物活性

Ketorolac tromethamine salt (RS37619 tromethamine salt) is a non-steroidal anti-inflammatory agent, acting as a nonselective COX inhibitor, with IC50s of 20 nM for COX-1 and 120 nM for COX-2.

性状

Solid

IC50 & Target[1][2]

COX-1

20 nM (IC50)

COX-2

120 nM (IC50)

体外研究(In Vitro)

Ketorolac is a non-steroidal anti-inflammatory agent, acting as a nonselective COX inhibitor, with IC50s of 20 nM for COX-1 and 120 nM for COX-2.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)

Ketorolac tromethamine (0.4%) causes nearly complete inhibition on LPS endotoxin-induced increases in FITC-dextran in the anterior chamber, and increases in aqueous PGE2 concentrations in the aqueous humor in rabbits. Ketorolac (30 mg/kg, i.v.) rapidly reverses hyperalgesia in rats. Ketorolac also reduces carrageenan-induced hyperalgesia and paw PG production, and causes reduction in PGE2 levels in rats. Ketorolac (4 mg/kg/day, p.o.) has no detrimental effect in the volume fraction of bone trabeculae formed inside the alveolar socket in rats. Ketorolac (60 μg/10 μL) reduces the histological changes such as ischemic cell death, including cytoplasmic eosinophilia with disintegration of cytoarchitecture and nuclear pyknosis in rats. Ketorolac also effectively reduces neuronal death and improves hindlimb motor function, and the long-term survival is similar to that in the control group.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

运输条件

Room temperature or refrigerated transportation.

储存方式

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

ClinicalTrial
参考文献
溶解度数据
体外研究: 

H2O : 100 mg/mL (265.67 mM; Need ultrasonic)

DMSO : ≥ 30 mg/mL (79.70 mM)

* "≥" means soluble, but saturation unknown.

配制储备溶液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.6567 mL 13.2837 mL 26.5675 mL
5 mM 0.5313 mL 2.6567 mL 5.3135 mL
10 mM 0.2657 mL 1.3284 mL 2.6567 mL
*

产品不同,其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液;配成溶液后,建议分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C 储存时,建议在 6 个月内使用,-20°C 储存时,建议在 1 个月内使用。

体内研究:

建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 体外研究 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    建议依照次序添加每种溶剂: PBS

    Solubility: 100 mg/mL (265.67 mM); Clear solution; Need ultrasonic

  • 2.

    建议依照次序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (5.53 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (5.53 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH?O 中,得到澄清透明的生理盐水溶液
  • 3.

    建议依照次序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (5.53 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (5.53 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 4.

    建议依照次序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (5.53 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (5.53 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2